HemaSphere (Jun 2022)
P684: PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
- W. Xu,
- R. Feng,
- L. Wang,
- Y. Song,
- H. Zhu,
- L. Fan,
- X. Guo,
- X. Wei,
- N. Lin,
- C. Xu,
- Z. Wang,
- X. Xiao,
- Y. Shen,
- Y. Chen,
- Y. Chen,
- F. Tan,
- S. P. Anthony,
- J. Li
Affiliations
- W. Xu
- 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing
- R. Feng
- 2 Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou
- L. Wang
- 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing
- Y. Song
- 3 Department of Lymphoma, Beijing Cancer Hospital, Beijing
- H. Zhu
- 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing
- L. Fan
- 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing
- X. Guo
- 2 Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou
- X. Wei
- 2 Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou
- N. Lin
- 3 Department of Lymphoma, Beijing Cancer Hospital, Beijing
- C. Xu
- 4 Phase I Unit, Nanfang Hospital of Southern Medical University
- Z. Wang
- 5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- X. Xiao
- 5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Y. Shen
- 5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- Y. Chen
- 6 Department of Clinical Development, Newave Pharmaceutical Inc., Pleasanton, United States of America
- Y. Chen
- 6 Department of Clinical Development, Newave Pharmaceutical Inc., Pleasanton, United States of America
- F. Tan
- 5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China
- S. P. Anthony
- 6 Department of Clinical Development, Newave Pharmaceutical Inc., Pleasanton, United States of America
- J. Li
- 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing
- DOI
- https://doi.org/10.1097/01.HS9.0000845620.15294.74
- Journal volume & issue
-
Vol. 6
pp. 580 – 581
Abstract
No abstracts available.